Compare Boston Scientific Corporation (BSX) vs Synopsys, Inc. (SNPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Synopsys, Inc. — how do they compare? Boston Scientific Corporation trades at $51.15 (market cap $71.46B), while Synopsys, Inc. trades at $410 (market cap $78.83B). The key difference: Boston Scientific Corporation and Synopsys, Inc. are close in size by market cap. Which is the better fit depends on your goals.
| BSX | SNPS | |
|---|---|---|
Market Cap | $71.46B | $78.83B |
Sector | Health | Technology |
52-Week High | $108.14 | $625.80 |
52-Week Low | $42.63 | $372.33 |
Enterprise Value | $83.55B | $87.19B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $49.31, up slightly by 0.02% on the day, with a bullish technical signal from moving averages despite overbought RSI readings near 77–83. The company reported strong Q2 2026 results, beating EPS estimates with $0.86 actual versus $0.835 expected, and revenue growth of 7.5%. Fundamentals show robust profitability with a net income margin of 17.5% and ROE of 15.52%, though 2026 guidance was trimmed due to WATCHMAN and electrophysiology segment pressures.
BSX presents a compelling investment case with 86% analyst buy ratings and a $67.21 consensus price target implying 36% upside. Key risks include competitive pressures in medical devices and execution on cost savings. The stock's valuation at a P/E of 19.96 appears reasonable given earnings growth, but investors must weigh near-term headwinds against long-term innovation catalysts.
Synopsys (SNPS) trades at $415.99, up 2.47% with strong technical momentum near resistance at $419. The stock shows robust fundamentals with consistent earnings beats (Q1 2026 EPS of $3.35 vs. $3.15 expected) and revenue growth to $7.05B in 2025. Recent developments include strategic AI partnerships with AMD and Microsoft, positioning the company at the forefront of chip design innovation.
Outlook remains positive with analyst consensus target of $559.50 suggesting 34% upside, though high P/E of 95.19 and aggressive cash flow investments in 2025-2026 present valuation and execution risks. The stock's bullish technical setup and strong institutional support outweigh near-term concerns for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Read more on SNPS →
